key: cord-0986748-vz7nlz6j
authors: Quintavalle, Gabriele; Coppola, Antonio; Ruggieri, Alessandro; Franca Rivolta, Gianna; Fronti, Elisa; Giangregorio, Francesco; Michieletti, Emanuele; Tagliaferri, Annarita
title: Severe bleeding in a patient with Factor XIII deficiency and COVID‐19
date: 2020-06-09
journal: Haemophilia
DOI: 10.1111/hae.14088
sha: 92137221ae110054f4ebd66d4aee8023cac30606
doc_id: 986748
cord_uid: vz7nlz6j

Since the outbreak in last December of the novel severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in Wuhan, China, scientific literature is providing essential contributions to elucidate the pathophysiological and clinical features of the Coronavirus disease 2019 (COVID‐19).(1) Consistent evidence shows that COVID‐19 is associated with significant changes in coagulation laboratory testing, mainly prolonged prothrombin time and elevated D‐dimer.(2)

This article is protected by copyright. All rights reserved ). 1 Consistent evidence shows that COVID-19 is associated with significant changes in coagulation laboratory testing, mainly prolonged prothrombin time and elevated D-dimer. 2 These abnormalities reflect the activation of coagulation system and hyperfibrinolysis, induced by the acute lung injury, hypoxia and the consequent inflammatory responses, which in turn amplify in a vicious cycle. This results in a hypercoagulable state and high thrombotic risk, correlated with poor prognosis and potentially leading to overt disseminated intravascular coagulation in most severe cases. 2 Epidemiologic and clinical data about COVID-19 in congenital bleeding disorders (CBD) are substantially lacking. To date, to our best knowledge only a casereport about a patient with severe hemophilia A and a mild form of COVID-19 has been published. 3 Herein we describe the case of a woman with inherited Factor XIII (FXIII) deficiency, admitted because of COVID-19 and a concomitant severe abdominal hematoma.

This 61-year-old woman was diagnosed in 1973 after post-surgical massive bleeding (FXIII Antigen 1.6%) and thereafter received replacement treatment on demand (1-2 traumatic bleeding episodes per year). She presented on March 10 th fever (until 38.5°C) and cough after close contacts with her mother affected by COVID-19. Antibiotics (azithromycin and ciprofloxacin) and then hydroxychloroquine were prescribed at home. On March 24 th she went to Accepted Article the emergency room because of persistent cough, abdominal pain and diarrhea. On admission, laboratory tests showed mild anemia (hemoglobin 10.2 g/dL) and lymphopenia (0.85x10 3 /µL); normal total leukocyte count and liver and kidney function tests; elevated CPK (880 U/L), D-dimer (2540 ng/mL) and CRP (5.51 mg/dL). The detection of viral RNA at oropharyngeal swab (RT-PCR) confirmed the diagnosis of SARS-CoV-2 infection. Chest computed tomography (CT) revealed small areas of ground-glass opacities in the lung lower lobes (visual score 10-15% of parenchyma involvement). Low-flow oxygen support (1-2 L/min) was needed. Antiviral treatment (darunavir/cobicistat) was started, together with antibiotic cover with piperacillin/tazobactam. Indeed, due to the patient's history of gallbladder stones, the abdominal pain was initially ascribed to acute cholecystitis. However, the detection of a pelvic mass at abdomen ultrasound (US), led to perform a CT, that revealed a large hematoma (23x6 cm) involving rectus muscles from epigastrium to pelvis, with signs of active bleeding after contrast agent injection. The patient received plasmaderived FXIII concentrate (Cluviat  , CSL Behring; 2500 IU, 32 IU/Kg), and underwent arteriography with embolization of the right epigastric artery, which led to cessation of bleeding. FXIII Antigen levels were 57.2% and 44.7%, 20 and 72 hours after the infusion of FXIII concentrate, respectively. A packed red cell unit was transfused due to anemia (Hb 8.7 g/dL). Five days later, FXIII concentrate (1250 IU) was further administered in order to maintain the hemostatic response. At CT reassessment decreased dimensions of the hematoma (maximum diameter 15 cm) and absence of active bleeding were shown. Over the following days, the patient's hematological and respiratory conditions improved. The oxygen support was gradually reduced until suspension and COVID-19 related treatments (hydroxychloroquine, azithromycin and antiviral therapy) were stopped by April 03 rd . At the same time, stable Hb levels and reduction of abdominal pain and hematoma at US assessment were observed. This clinical picture and the ongoing hemostatic treatment with FXIII concentrate enabled to start thromboprophylaxis, usually prescribed in COVID-19 patients since the admission. 4 According to local protocols, weight-adjusted doses of low molecular weight heparin (enoxaparin 70 IU/Kg/day; body mass index 30.5) were given. FXIII levels were maintained >25-30% to achieve protection from bleeding risk. Indeed, FXIII concentrate 1250 IU was administered 14 days after the previous infusion (FXIII 29%) and further prophylactic coverage was planned every 10-14 days. After negative RT-PCR on two consecutive oropharyngeal swabs, the patient was

This article is protected by copyright. All rights reserved discharged on April 15 th , being mild anemia and lymphopenia still present. Enoxaparin was suspended 5 days later. The following clinical course was uneventful. On April 22 nd at an outpatient visit at the hemophilia center, mild abdominal swelling and rigidity were found, together with resolution of anemia and lymphopenia. The patient's clinical course is represented in Table 1 .

This report of a patient with FXIII deficiency adds information about clinical features and management of COVID-19 in subjects with CBD. In a recent description of a patient with severe hemophilia A, no bleeding symptoms or complications were reported. 3 Similarly to that case, our patient suffered from a mild form of COVID-19. Hospitalization was not due to respiratory insufficiency, but to symptoms of severe bleeding. Indeed, a massive muscle hematoma was diagnosed, likely triggered by persistent coughing fits, which induced abnormal strains of the abdomen wall. This clinical presentation highlights the issue of bleeding risk in CBD patients with COVID-19. 5 Bleeding symptoms are uncommon in COVID-19 and the reported coagulation abnormalities does not result in hemorrhagic tendency; however, additional risks for CBD patients over the course of disease are due to invasive procedures (arterial punctures for blood gas analysis, central venous access insertion, invasive ventilation) and some pharmacological treatments. 5 These include corticosteroids, non-steroidal anti-inflammatory drugs and, particularly, antithrombotic strategies. The thrombotic risk of COVID-19, with lung microvascular thrombosis as well venous thromboembolism, is increasingly reported. 4 Therefore, thromboprophylaxis with LMWH at least at standard doses is strongly recommended, with some authors also suggesting therapeutic doses, aimed at affecting thromboinflammatory mechanisms. 4 Thromboprophylaxis is also advised in the pre-hospital phase and after discharge, according to the individual risk profile. 4 Whether the CBD can modify the thrombotic tendency in COVID-19 is currently unknown. On the other hand, it is now recognized that CBD patients are not protected from cardiovascular/thromboembolic diseases and that they can receive antithrombotic treatments with the same modalities than non-coagulopathic subjects, provided that concomitant anti-hemorrhagic prophylaxis is given. [6] [7] [8] Evidence-based guidelines are not available in this setting, therefore strategies rely on expert suggestions and the careful

This article is protected by copyright. All rights reserved assessment of individual bleeding and thrombotic/cardiovascular risk. 8 These concepts can be extrapolated to CBD patients with COVID-19, in order to manage their bleeding risk due to thromboprophylaxis and other predisposing conditions, during hospitalization and in the hometreatment setting, if needed. 5 Despite the high bleeding risk, our patient was able to safely receive LMWH maintaining sustained FXIII levels through specific replacement treatment. Due to the rarity of congenital FXIII deficiency, limited information about treatment and safe factor levels are available. However, the long half-life of FXIII concentrate facilitates the achievement of high trough levels with infusion intervals >7-10 days. 9 This case remarks that prompt identification of CBD patients and contact with specialist hemophilia centers are crucial for safe and effective management. 10 FXIII deficiency could be missed as patients show normal first-level coagulation tests. Moreover, specific laboratory testing and replacement products are often not available, particularly in the emergency setting.

Ongoing national and international studies will hopefully help clarify the numerous unanswered issues of COVID-19 in CBD patients.

GQ has acted as a paid consultant to Bayer; AC has acted as a paid consultant to Bayer and Novo Nordisk and received speaker fees by Novo Nordisk and Werfen; AT has acted as an advisory board member to Bayer, Roche and Novo Nordisk and received speaker fees by Novo Nordisk. AR, GFR, EF, FG and EM have nothing to declare. 

Clinical Characteristics of Coronavirus Disease 2019 in China

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Clinical findings in a patient with haemophilia A affected by COVID-19

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Confronting COVID-19: Issues in hemophilia and congenital bleeding disorders

History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia

Occurrence of thrombosis in rare bleeding disorders

New concepts for anticoagulant therapy in persons with hemophilia

Clinical Use of Factor XIII Concentrates

A web site to improve management of patients with inherited bleeding disorders in the Emergency Department: Results at 2 years

This article is protected by copyright. All rights reserved